Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $42.60.

Several brokerages have recently issued reports on COLL. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Piper Sandler reiterated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th.

Collegium Pharmaceutical Price Performance

COLL opened at $29.96 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock’s 50 day simple moving average is $35.69 and its 200 day simple moving average is $34.77. The firm has a market cap of $966.21 million, a price-to-earnings ratio of 12.91 and a beta of 0.95. Collegium Pharmaceutical has a 1 year low of $25.16 and a 1 year high of $42.29.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 13.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. boosted its holdings in Collegium Pharmaceutical by 3.2% in the first quarter. Russell Investments Group Ltd. now owns 33,084 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after acquiring an additional 1,011 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Collegium Pharmaceutical by 55.8% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,410 shares of the specialty pharmaceutical company’s stock worth $598,000 after purchasing an additional 5,520 shares in the last quarter. Vanguard Group Inc. grew its position in Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after purchasing an additional 17,942 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in Collegium Pharmaceutical by 17.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,852 shares of the specialty pharmaceutical company’s stock valued at $1,235,000 after purchasing an additional 4,742 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Collegium Pharmaceutical by 1.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company’s stock worth $1,137,000 after buying an additional 535 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.